Conjunctivitis, or pink eye, is inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid due to numerous causes the most common being bacterial infection. The condition is self-limiting, but in some cases results in kerato-conjunctivitis, which results in blurred vision. The viral and bacterial conjunctivitis results in highly infectious watery discharge which is extremely contagious.
This report contains market size and forecasts of Conjunctivitis Drugs in global, including the following market information:
- Global Conjunctivitis Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Conjunctivitis Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Conjunctivitis Drugs companies in 2021 (%)
The global Conjunctivitis Drugs market was valued at 894.6 million in 2021 and is projected to reach US$ 1005.4 million by 2028, at a CAGR of 1.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Antibiotics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Conjunctivitis Drugs include Akorn Pharmaceuticals, Alcon/ Novartis, Allergan, Bausch & Lomb, Bausch Health, Merck, Actavis and Pfizer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Conjunctivitis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Conjunctivitis Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Conjunctivitis Drugs Market Segment Percentages, by Type, 2021 (%)
- Antibiotics
- Mast Cell Stabilizers
- Steroids
- Others
Global Conjunctivitis Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Conjunctivitis Drugs Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Self-Administered
Global Conjunctivitis Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Conjunctivitis Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Conjunctivitis Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Conjunctivitis Drugs revenues share in global market, 2021 (%)
- Key companies Conjunctivitis Drugs sales in global market, 2017-2022 (Estimated), (K Units)
- Key companies Conjunctivitis Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Akorn Pharmaceuticals
- Alcon/ Novartis
- Allergan
- Bausch & Lomb
- Bausch Health
- Merck
- Actavis
- Pfizer
